In its upcoming report, Exelixis (EXEL) is predicted by Wall Street analysts to post quarterly earnings of $0.42 per share, reflecting an increase of 147.1% compared to the same period last year. Revenues are forecasted to be $502.96 million, representing a year-over-year increase of 18.3%.
The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Exelixis metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Net product' to reach $448.24 million. The estimate indicates a year-over-year change of +18.4%.
Analysts expect 'Revenues- Net product- CABOMETYX' to come in at $433.73 million. The estimate indicates a year-over-year change of +15.2%.
According to the collective judgment of analysts, 'Revenues- License' should come in at $44.61 million. The estimate indicates a year-over-year change of -0.2%.
View all Key Company Metrics for Exelixis here>>>
Shares of Exelixis have experienced a change of +4.2% in the past month compared to the +11.3% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EXEL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
